Skip to main content
SpringerLink
Log in

Reply to: Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kong JC, Soucisse M, Michael M, et al. Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09837-8.

  2. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15.

    Article  CAS  Google Scholar 

  3. Garant A, Kavan P, Martin AG, et al. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: the KIR randomized phase II trial. Radiother Oncol. 2021;155:237–45.

    Article  CAS  Google Scholar 

  4. Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212–22.

    Article  CAS  Google Scholar 

  5. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    Joseph C. Kong MBChB, FRACS, MS, PhD & Alexander G. Heriot FRACS, MD

  2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia

    Joseph C. Kong MBChB, FRACS, MS, PhD, Sam Ngan MBBS, FRANZCR, Jeanne Tie MBChB, FRACP, MD & Alexander G. Heriot FRACS, MD

  3. Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    Sam Ngan MBBS, FRANZCR

  4. Division of Radiation Oncology, Peter MacCallum Cancer Centre,, Melbourne, VIC, Australia

    Jeanne Tie MBChB, FRACP, MD

Authors
  1. Joseph C. Kong MBChB, FRACS, MS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sam Ngan MBBS, FRANZCR
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeanne Tie MBChB, FRACP, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander G. Heriot FRACS, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph C. Kong MBChB, FRACS, MS, PhD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kong, J.C., Ngan, S., Tie, J. et al. Reply to: Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not. Ann Surg Oncol 28 (Suppl 3), 795–796 (2021). https://doi.org/10.1245/s10434-021-10434-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10434-y

Search

Navigation